BM
Therapeutic Areas
Protara Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TARA-002 | Non-Muscle Invasive Bladder Cancer (NMIBC), BCG-unresponsive carcinoma in situ (CIS) with/without papillary tumors | Phase 2 |
| IV Choline Chloride | Intestinal Failure-Associated Liver Disease (IFALD) | Phase 2 |
Leadership Team at Protara Therapeutics
JS
Jesse Shefferman
Chief Executive Officer
JA
Julianne Averill
Chief Financial Officer
HF
Hannah Frye, MD
Chief Medical Officer
RG
Richard G. Baum
Chief Operating Officer & General Counsel
ML
Michael L. Levitt
Chairman of the Board
PF
Patrick Fabbio
Director
RD
Richard Dean
Director
RJ
Robert J. Spiegel, M.D.
Director
JR
James R. Sulat
Director